Verastem Oncology Discontinues RAMP 203 Trial to Focus on VS-7375 Development
Verastem Oncology announced that following evaluation of interim data from the RAMP 203 clinical trial in advanced KRAS G12C-mutated non-small cell lung cancer it will discontinue the trial to focus resources on clinical development of VS-7375, an oral KRAS G12D inhibitor, in advanced NSCLC and other solid tumors. There will be no further enrollment and patients currently enrolled will have the option to continue treatment per investigator discretion. This decision reflects the evolving treatment landscape for KRAS G12C inhibitors and the strategic prioritization of programs with the greatest potential impact for patients living with advanced lung cancer. "RAMP 203 has provided important insights into treatment strategies and demonstrated proof-of-concept. While avutometinib plus defactinib combined well with a G12C inhibitor to drive early and sustained anti-tumor responses, next generation G12C inhibitors are establishing a new benchmark with higher response rates. Accordingly, we are prioritizing our clinical development of VS-7375, a potentially best-in-class oral KRAS G12D (ON/OFF) inhibitor, that demonstrated a 69% response rate (11 of 16, both confirmed and unconfirmed) in advanced KRAS G12D NSCLC and has the potential to help more patients with its differentiated approach in multiple solid tumors; and the RAMP 205 clinical trial evaluating avutometinib plus defactinib in combination with chemotherapy in first line metastatic pancreatic cancer," said John Hayslip, chief medical officer at Verastem Oncology. "We sincerely appreciate and thank the investigators, patients, and families who participated in this program as these clinical outcomes will contribute to the development of novel therapies urgently needed for this challenging cancer."
Trade with 70% Backtested Accuracy
Analyst Views on VSTM
About VSTM
About the author
Verastem Discontinues RAMP 203 Trial, Shifts Focus to VS-7375
- Trial Termination: Verastem Oncology announced the discontinuation of the RAMP 203 trial due to increased competition and higher response benchmarks, halting patient enrollment while allowing current patients to continue treatment at the investigator's discretion, highlighting the challenging market environment.
- Resource Reallocation: The company will redirect resources to VS-7375, an oral KRAS G12D inhibitor that has demonstrated a 69% response rate in 16 patients, indicating its potential in advanced non-small cell lung cancer and other solid tumors.
- Strategic Potential: Management cited stronger strategic potential for VS-7375 in an SEC filing, particularly with ongoing progress in RAMP 205, which evaluates the combination of avutometinib and defactinib with chemotherapy.
- Market Reaction: Following the announcement, Verastem's stock fell 4.34% to $7.75, reflecting investor concerns about the company's future prospects, which may impact its financing and R&D capabilities.
TEN Holdings Inc. Raises $2.25M in Private Placement, Shares Surge 17%
- Successful Private Placement: TEN Holdings Inc. announced a private placement of 991,000 shares at $2.27 each, raising $2.25 million, with shares climbing 17% to $1.65 in after-hours trading, indicating strong market confidence in its financing strategy.
- Acquisition Agreement Signed: Fonar Corp. revealed it has signed a definitive agreement for a “take private” sale, resulting in a 24% surge in shares to $18.18 in after-hours trading, reflecting investor optimism regarding the company's privatization prospects.
- FDA Application Submitted: CapsoVision Inc. submitted its 510(k) application for its proprietary AI-assisted module to the FDA, although shares dipped 11% to $11.58 on Monday, this development may pave the way for future market access.
- Clinical Study Discontinuation: Verastem Inc. announced the discontinuation of its RAMP 203 clinical study, leading to a 2.7% drop in shares to $7.55 in after-hours trading, highlighting market concerns over its clinical progress.
